Back to Results

Neurosense Therapeutics Ltd (NRSN)

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases in the United States and other international markets. Its lead candidate, PrimeC, is an extended-release oral combination of ciprofloxacin and celecoxib that is being studied in Phase 2b/3 trials for amyotrophic lateral sclerosis. The company has also completed Phase 2 testing of PrimeC in Alzheimer’s disease and is evaluating it further in preclinical work for Parkinson’s disease. In addition, NeuroSense’s preclinical pipeline includes StabiliC for Parkinson’s disease and CogniC for Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-NRSN
$7.52
18.4% Upside
Undervalued
$133.33 1,999.7% Upside
Not available
Bargain
Weak
0.0%
December 2, 2026
11.739 M
11.743 M
1.3%
67.5%
-232.5
69.0%
Valuation • Fair Value

Neurosense Therapeutics Ltd (NASDAQ-NRSN) Fair Value by Valuation Model

Review the available estimates for Neurosense Therapeutics Ltd (NASDAQ-NRSN), including Comps Fair Value.

Primary Valuation Read

Fair Value

$7.52

Estimated upside of 18.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$7.52

Comparable-company valuation reference.

Analyst Price Target

$133.33 1,999.7% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for Neurosense Therapeutics Ltd (NASDAQ-NRSN) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Neurosense Therapeutics Ltd (NASDAQ-NRSN)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-11.069 M

Current operating profitability reference.

EBITDA Forecast

-13.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Neurosense Therapeutics Ltd (NASDAQ-NRSN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Neurosense Therapeutics Ltd (NASDAQ-NRSN)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-232.5

Lower score that deserves closer risk review.

FCF / Net Income

69.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Neurosense Therapeutics Ltd (NASDAQ-NRSN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Neurosense Therapeutics Ltd (NASDAQ-NRSN)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 2, 2026

Days to Earnings

75

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Neurosense Therapeutics Ltd (NASDAQ-NRSN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Neurosense Therapeutics Ltd (NASDAQ-NRSN) Stock Forecast & Technical Outlook

Review Neurosense Therapeutics Ltd (NASDAQ-NRSN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Neurosense Therapeutics Ltd (NASDAQ-NRSN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Neurosense Therapeutics Ltd (NASDAQ-NRSN) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Neurosense Therapeutics Ltd (NASDAQ-NRSN) Stock FAQ

Data-supported answers about Neurosense Therapeutics Ltd (NASDAQ-NRSN), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.52
Estimated upside 18.4%
Valuation Rating
Undervalued
Estimated upside of 18.4%
Analyst Target
$133.33 1,999.7% Upside
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is $7.52. This implies an estimated upside of 18.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 18.4% versus the current market price.

The available analyst price target for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is $133.33 1,999.7% Upside.

The current financial health read for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Neurosense Therapeutics Ltd (NASDAQ-NRSN) is December 2, 2026.

The latest available data indicates no current dividend yield for Neurosense Therapeutics Ltd (NASDAQ-NRSN).

The current market capitalization listed for Neurosense Therapeutics Ltd is 11.739 M.

The current enterprise value listed for Neurosense Therapeutics Ltd is 11.743 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Neurosense Therapeutics Ltd is NASDAQ-NRSN, and the stock is listed on NASDAQ.

Neurosense Therapeutics Ltd (NASDAQ-NRSN) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Neurosense Therapeutics Ltd is 1.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Neurosense Therapeutics Ltd is 67.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B